No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health
Summary
Going forward, the synthetic biology company will focus exclusively on human health under the name of a subsidiary whose lead cell therapies are now in early-stage clinical testing in cancer. Germantown, MD-based Intrexon (NASDAQ: XON) announced Thursday that it will change its name to Precigen, which is the cell and gene therapy business unit it formed in 2018. As part of the new corporate identity, Intrexon says it will change its stock symbol from “XON” to “PGEN.” Intrexon’s Precigen unit aims to improve upon current cancer cell therapies with an approach that could offer manufacturing advantages and fewer side effects. In a November conference call to discuss the Precigen pipeline, Sabzevari reported that the company was able to produce its therapies and infuse them in patients at two different clinical trial sites, according to a Seeking Alpha transcript. In addition to the therapies in Precigen’s pipeline, the new Precigen will encompass two other Intrexon healthcare subsidiaries: ActoBio Therapeutics and Exemplar Genetics, and a majority stake in cardiovascular gene-therapy developer Triple-Gene.
Classifications
AskAI Classifications
LabelsLinked Companies
